Matinas BioPharma Holdings Book Value Per Share Growth & History (MTNB)
Matinas BioPharma Holdings's book value per share was $0.75 for fiscal 2025.
View full Matinas BioPharma Holdings company overviewMatinas BioPharma Holdings annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0.75 | -$0.74 | −49.47% |
| 2024 | 2024-12-31 | $1.49 | -$2.94 | −66.31% |
| 2023 | 2023-12-31 | $4.43 | -$4.00 | −47.47% |
| 2022 | 2022-12-31 | $8.43 | -$3.70 | −30.53% |
| 2021 | 2021-12-31 | $12.14 | -$2.84 | −18.96% |
| 2020 | 2020-12-31 | $14.98 | $6.07 | +68.12% |
| 2019 | 2019-12-31 | $8.91 | $1.78 | +25.03% |
| 2018 | 2018-12-31 | $7.12 | $1.40 | +24.55% |
| 2017 | 2017-12-31 | $5.72 | $4.81 | +525.57% |
| 2016 | 2016-12-31 | $0.91 | -$4.40 | −82.78% |
| 2015 | 2015-12-31 | $5.31 | $1.86 | +53.93% |
| 2014 | 2014-12-31 | $3.45 | -$12.92 | −78.92% |
| 2013 | 2013-12-31 | $16.37 | — | — |
Matinas BioPharma Holdings quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0.28 | -$1.23 | −81.38% |
| Q1 2026 | 2026-03-31 | $0.47 | -$0.76 | −61.73% |
| Q4 2025 | 2025-12-31 | $0.75 | -$0.74 | −49.47% |
| Q3 2025 | 2025-09-30 | $1.09 | -$2.01 | −64.71% |
| Q2 2025 | 2025-06-30 | $1.51 | -$2.30 | −60.38% |
| Q1 2025 | 2025-03-31 | $1.23 | -$2.11 | −63.17% |
| Q4 2024 | 2024-12-31 | $1.49 | -$2.94 | −66.31% |
| Q3 2024 | 2024-09-30 | $3.10 | -$2.23 | −41.78% |
| Q2 2024 | 2024-06-30 | $3.81 | -$2.60 | −40.59% |
| Q1 2024 | 2024-03-31 | $3.35 | -$4.16 | −55.42% |
| Q4 2023 | 2023-12-31 | $4.43 | -$4.00 | −47.47% |
| Q3 2023 | 2023-09-30 | $5.33 | -$3.58 | −40.17% |
| Q2 2023 | 2023-06-30 | $6.41 | -$3.47 | −35.11% |
| Q1 2023 | 2023-03-31 | $7.51 | -$3.49 | −31.70% |
| Q4 2022 | 2022-12-31 | $8.43 | -$3.70 | −30.53% |
| Q3 2022 | 2022-09-30 | $8.90 | -$4.57 | −33.89% |
| Q2 2022 | 2022-06-30 | $9.88 | -$4.77 | −32.58% |
| Q1 2022 | 2022-03-31 | $10.99 | -$4.40 | −28.57% |
| Q4 2021 | 2021-12-31 | $12.14 | -$2.84 | −18.96% |
| Q3 2021 | 2021-09-30 | $13.47 | -$2.67 | −16.56% |
| Q2 2021 | 2021-06-30 | $14.65 | -$2.66 | −15.36% |
| Q1 2021 | 2021-03-31 | $15.39 | -$3.28 | −17.57% |
| Q4 2020 | 2020-12-31 | $14.98 | $6.07 | +68.12% |
| Q3 2020 | 2020-09-30 | $16.14 | $4.47 | +38.33% |
| Q2 2020 | 2020-06-30 | $17.31 | $3.30 | +23.54% |
| Q1 2020 | 2020-03-31 | $18.67 | $3.63 | +24.16% |
| Q4 2019 | 2019-12-31 | $8.91 | $1.78 | +25.03% |
| Q3 2019 | 2019-09-30 | $11.67 | $6.40 | +121.39% |
| Q2 2019 | 2019-06-30 | $14.01 | $7.37 | +110.85% |
| Q1 2019 | 2019-03-31 | $15.04 | $10.55 | +235.15% |
| Q4 2018 | 2018-12-31 | $7.12 | $1.40 | +24.55% |
| Q3 2018 | 2018-09-30 | $5.27 | -$1.61 | −23.35% |
| Q2 2018 | 2018-06-30 | $6.65 | -$1.62 | −19.61% |
| Q1 2018 | 2018-03-31 | $4.49 | -$2.55 | −36.27% |
| Q4 2017 | 2017-12-31 | $5.72 | $4.81 | +525.57% |
| Q3 2017 | 2017-09-30 | $6.88 | $4.60 | +202.26% |
| Q2 2017 | 2017-06-30 | $8.27 | $5.67 | +217.73% |
| Q1 2017 | 2017-03-31 | $7.04 | $3.38 | +92.15% |
| Q4 2016 | 2016-12-31 | $0.91 | -$4.40 | −82.78% |
| Q3 2016 | 2016-09-30 | $2.28 | -$3.81 | −62.60% |
| Q2 2016 | 2016-06-30 | $2.60 | -$4.97 | −65.64% |
| Q1 2016 | 2016-03-31 | $3.66 | -$3.17 | −46.38% |
| Q4 2015 | 2015-12-31 | $5.31 | $1.86 | +53.93% |
| Q3 2015 | 2015-09-30 | $6.08 | -$1.29 | −17.52% |
| Q2 2015 | 2015-06-30 | $7.57 | -$2.52 | −24.94% |
| Q1 2015 | 2015-03-31 | $6.83 | -$6.62 | −49.20% |
| Q4 2014 | 2014-12-31 | $3.45 | -$12.92 | −78.92% |
| Q3 2014 | 2014-09-30 | $7.38 | — | — |
| Q2 2014 | 2014-06-30 | $10.09 | — | — |
| Q1 2014 | 2014-03-31 | $13.45 | — | — |
| Q4 2013 | 2013-12-31 | $16.37 | — | — |
Matinas BioPharma Holdings book value per share trends
Over the last five fiscal years, Matinas BioPharma Holdings's book value per share decreased from $14.98 to $0.75, a change of -$14.22. The latest reported quarter, Q2 2026, shows $0.28.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Matinas BioPharma Holdings source filings ↗